Jardiance 10 mg, 25 mg FC tablets
PDF Leaflet Revision Date: 27 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to diet and exercise for glycaemic control in adults with type 2 diabetes mellitus.
Dosage (summary)
Starting dose: 10 mg once daily; may increase to 25 mg if tolerated.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Increased risk of hypoglycaemia with insulin or sulphonylureas
- Lithium levels may decrease
Contraindications
- Type 1 diabetes mellitus
- Ketoacidosis
- Hypersensitivity to empagliflozin
Common side effects
- Hypoglycaemia
- Volume depletion
- Genital infections
Counselling Points
- Monitor for signs of ketoacidosis
- Stay hydrated
- Report any genital infections
Serious warnings
- Risk of ketoacidosis
- Monitor renal function
- Risk of Fournier's gangrene
Important Disclaimer
The Jardiance 10 mg, 25 mg FC tablets professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
